Last reviewed · How we verify

Sevoflurane+Propofol

Huazhong University of Science and Technology · FDA-approved active Small molecule

Sevoflurane and propofol are combined inhalational and intravenous anesthetics that enhance GABAergic inhibitory neurotransmission to produce sedation, hypnosis, and anesthesia.

Sevoflurane and propofol are combined inhalational and intravenous anesthetics that enhance GABAergic inhibitory neurotransmission to produce sedation, hypnosis, and anesthesia. Used for General anesthesia for surgical procedures, Sedation during anesthesia maintenance.

At a glance

Generic nameSevoflurane+Propofol
Also known asSevoflurane and Propofol
SponsorHuazhong University of Science and Technology
Drug classGeneral anesthetic combination
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Sevoflurane is a volatile anesthetic that potentiates GABA-A receptor signaling in the central nervous system, while propofol is an intravenous anesthetic with similar GABAergic mechanisms. Together, they provide synergistic anesthetic effects, allowing for reduced dosing of each agent while maintaining adequate anesthesia during surgical procedures. This combination is used to optimize the balance between anesthetic depth and hemodynamic stability.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: